Cost-effectiveness of lazertinib as first-line treatment in patients with -mutated advanced lung cancer
Background: Lazertinib demonstrates efficacy similar to that of osimertinib in the first-line treatment of epidermal growth factor receptor ( EGFR )-mutated advanced lung cancer. However, its cost-effectiveness has not yet been evaluated. Objective: To study the cost-effectiveness of lazertinib as a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241312143 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841560338681561088 |
|---|---|
| author | Li-Jung Elizabeth Ku Jui-Hung Tsai Li-Jun Chen Szu-Chun Yang |
| author_facet | Li-Jung Elizabeth Ku Jui-Hung Tsai Li-Jun Chen Szu-Chun Yang |
| author_sort | Li-Jung Elizabeth Ku |
| collection | DOAJ |
| description | Background: Lazertinib demonstrates efficacy similar to that of osimertinib in the first-line treatment of epidermal growth factor receptor ( EGFR )-mutated advanced lung cancer. However, its cost-effectiveness has not yet been evaluated. Objective: To study the cost-effectiveness of lazertinib as a first-line treatment for patients with EGFR -mutated advanced lung cancer. Design: A partitioned survival model-based cost-effectiveness analysis. Methods: We conducted the economic analysis from the perspective of the healthcare sector with a lifetime horizon. Simulated patients were entered into the models upon the diagnosis of EGFR -mutated advanced lung cancer. Lazertinib was compared with gefitinib. The model inputs were derived from the trials (survival outcomes, incidence of adverse events (AEs), and subsequent therapies), National Health Insurance payments (costs of drugs and AEs), and hospital cohorts (utility values). Deterministic and probabilistic analyses were also conducted. Results: Applying the same daily price of osimertinib (US$110) to that of lazertinib, the incremental cost-effectiveness ratio of lazertinib versus gefitinib was US$93,792 per quality-adjusted life year (QALY). The cost of lazertinib was a major determinant. If the daily price of lazertinib could be reduced to US$75, lazertinib would become cost-effective at a willingness-to-pay (WTP) threshold of US$70,000 per QALY. Given the WTP threshold, the probability that lazertinib would be cost-effective was 0.7%. Conclusion: Lazertinib is not a cost-effective first-line treatment for EGFR -mutated advanced lung cancer. Lowering prices enables cost-effectiveness. |
| format | Article |
| id | doaj-art-672f3ba54f5f460d984a9645934a54bf |
| institution | Kabale University |
| issn | 1758-8359 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-672f3ba54f5f460d984a9645934a54bf2025-01-04T09:03:19ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592025-01-011710.1177/17588359241312143Cost-effectiveness of lazertinib as first-line treatment in patients with -mutated advanced lung cancerLi-Jung Elizabeth KuJui-Hung TsaiLi-Jun ChenSzu-Chun YangBackground: Lazertinib demonstrates efficacy similar to that of osimertinib in the first-line treatment of epidermal growth factor receptor ( EGFR )-mutated advanced lung cancer. However, its cost-effectiveness has not yet been evaluated. Objective: To study the cost-effectiveness of lazertinib as a first-line treatment for patients with EGFR -mutated advanced lung cancer. Design: A partitioned survival model-based cost-effectiveness analysis. Methods: We conducted the economic analysis from the perspective of the healthcare sector with a lifetime horizon. Simulated patients were entered into the models upon the diagnosis of EGFR -mutated advanced lung cancer. Lazertinib was compared with gefitinib. The model inputs were derived from the trials (survival outcomes, incidence of adverse events (AEs), and subsequent therapies), National Health Insurance payments (costs of drugs and AEs), and hospital cohorts (utility values). Deterministic and probabilistic analyses were also conducted. Results: Applying the same daily price of osimertinib (US$110) to that of lazertinib, the incremental cost-effectiveness ratio of lazertinib versus gefitinib was US$93,792 per quality-adjusted life year (QALY). The cost of lazertinib was a major determinant. If the daily price of lazertinib could be reduced to US$75, lazertinib would become cost-effective at a willingness-to-pay (WTP) threshold of US$70,000 per QALY. Given the WTP threshold, the probability that lazertinib would be cost-effective was 0.7%. Conclusion: Lazertinib is not a cost-effective first-line treatment for EGFR -mutated advanced lung cancer. Lowering prices enables cost-effectiveness.https://doi.org/10.1177/17588359241312143 |
| spellingShingle | Li-Jung Elizabeth Ku Jui-Hung Tsai Li-Jun Chen Szu-Chun Yang Cost-effectiveness of lazertinib as first-line treatment in patients with -mutated advanced lung cancer Therapeutic Advances in Medical Oncology |
| title | Cost-effectiveness of lazertinib as first-line treatment in patients with -mutated advanced lung cancer |
| title_full | Cost-effectiveness of lazertinib as first-line treatment in patients with -mutated advanced lung cancer |
| title_fullStr | Cost-effectiveness of lazertinib as first-line treatment in patients with -mutated advanced lung cancer |
| title_full_unstemmed | Cost-effectiveness of lazertinib as first-line treatment in patients with -mutated advanced lung cancer |
| title_short | Cost-effectiveness of lazertinib as first-line treatment in patients with -mutated advanced lung cancer |
| title_sort | cost effectiveness of lazertinib as first line treatment in patients with mutated advanced lung cancer |
| url | https://doi.org/10.1177/17588359241312143 |
| work_keys_str_mv | AT lijungelizabethku costeffectivenessoflazertinibasfirstlinetreatmentinpatientswithmutatedadvancedlungcancer AT juihungtsai costeffectivenessoflazertinibasfirstlinetreatmentinpatientswithmutatedadvancedlungcancer AT lijunchen costeffectivenessoflazertinibasfirstlinetreatmentinpatientswithmutatedadvancedlungcancer AT szuchunyang costeffectivenessoflazertinibasfirstlinetreatmentinpatientswithmutatedadvancedlungcancer |